FDA approval win Soleno recently secured FDA approval for the first and only therapy addressing hyperphagia in Prader-Willi syndrome as of March 2025, signaling a validated clinical need and potential payer interest for downstream commercial activities.

Expansion opportunities With a recent presentation at ENDO 2026 and ongoing commercialization efforts for VYKAT XR, there may be opportunities to partner on educational campaigns, post-approval studies, and real-world evidence programs to support uptake.

Regulatory & risk Ongoing litigation and fiduciary-related investigations could affect market perception and stock volatility; proactive risk management and transparent diligence materials may help sales teams reassure KOLs and healthcare partners.

Financial strength Significant funding and a revenue base in the hundreds of millions, combined with a sizable funding cushion, provide capacity for rapid scale-up, payer negotiations, and expanded field force in the PWS space.

Market focus Specialization in Prader-Willi syndrome places Soleno in a narrow therapeutic niche with limited competitors; identify opportunities to collaborate with patient advocacy groups, specialty pharmacies, and payer programs to accelerate access.